A tau-clearing drug shows early promise against Alzheimer's, but the data comes with caveats

Verified key facts

• Detailed CELIA Phase 2 results for diranersen (BIIB080) were presented on 14 July 2026 at AAIC 2026 in London.
• The trial enrolled 416 people with early Alzheimer's disease and ran over 18 months.
• Topline data missed the primary endpoint, but pre-specified analyses showed slowing of decline across dose groups.
• Biomarker readouts showed sustained reductions in cerebrospinal-fluid tau and tau-PET signal at all doses tested.

A first for tau

Researchers have reported the first Phase 2 evidence that a drug can strip toxic tau tangles from the brain in early Alzheimer's disease. The therapy is called diranersen, also known as BIIB080. Biogen presented detailed results on 14 July 2026. The venue was the Alzheimer's Association International Conference in London.

Tau is one of two proteins long tied to Alzheimer's. When it misfolds, it forms tangles inside brain cells. Those tangles track closely with cognitive decline. A treatment that lowers tau has been a long-sought goal. The new data offers the clearest signal yet that the approach can work.

For decades, most Alzheimer's drug efforts chased amyloid, the other hallmark protein. Tau proved a harder target. Its tangles sit inside neurons, shielded from many therapies. Reaching them without harming the cell is difficult. That is why the CELIA signal, if it holds, carries such weight.

What the trial measured

The study, named CELIA, enrolled 416 people with early Alzheimer's disease. Participants were followed over 18 months. Investigators tracked both clinical scores and biological markers. The biomarkers included tau in cerebrospinal fluid and tau seen on brain scans.

According to Biogen, the therapy produced sustained reductions in tau at every dose evaluated. Pre-specified analyses also showed slowing of clinical decline across the studied dose groups. The team reported the most notable effect at the lowest dose tested. That result surprised some observers, who had expected larger doses to lead.

Measuring tau directly gives the data extra weight. Brain scans and spinal-fluid tests can show whether a drug hits its target. In CELIA, those readouts moved in the right direction. The harder question is whether that biology translates into a real difference for patients. That link is never guaranteed.

A complicated headline

The picture is not uniformly positive. Earlier topline data, reported before the London meeting, showed the trial missed its primary endpoint. Outlets covering the field, including NeurologyLive, flagged that miss clearly. A missed primary endpoint is a serious caveat in drug development.

Biogen argues that the fuller dataset tells a more encouraging story. The company points to consistent biomarker effects and slowing on several clinical measures. Independent experts will want to see the complete results published and reviewed. Early conference data can shift once peer scrutiny begins.

How the therapy works

Diranersen is an antisense oligonucleotide. That is a short strand of engineered genetic material. It targets MAPT, the gene that codes for tau. By acting on the messenger molecule, it lowers production of all tau forms.

The result, in theory, is less tau both inside and outside brain cells. Biogen developed the drug with partner Ionis. The mechanism differs from the amyloid-clearing antibodies approved in recent years. Those target a different protein. Diranersen would attack the disease from another angle.

The delivery route is worth noting. Antisense drugs of this kind are given directly into the spinal fluid. That is an involved procedure, not a simple pill. Any future rollout would have to weigh that burden. Convenience matters when treating a long-term disease.

Cautions and unknowns

This article reports research findings only. It does not offer treatment or dosage advice. Diranersen is experimental and not approved for general use. Anyone concerned about memory or dementia should speak with a qualified clinician.

Several questions remain open. Phase 2 trials are relatively small and short. They cannot confirm long-term safety or lasting benefit. The unusual dose response also needs explanation. Larger studies will test whether the early signal holds.

Funding and expectation add their own pressure. Alzheimer's is a vast market and an emotional one. That can shape how early results are framed. Careful reporting separates a promising signal from a proven cure. Diranersen sits firmly in the former camp for now.

A field hungry for progress

Alzheimer's disease affects tens of millions of people worldwide. That number is set to climb as populations age. Existing treatments do not stop the disease. The recently approved amyloid antibodies slow it modestly and carry real risks.

A tau-based approach could complement those drugs rather than replace them. Some scientists suspect future treatment will combine targets. Hit amyloid and tau together, the theory goes, and the benefit may compound. CELIA is one early test of whether the tau half of that bet can pay off.

The road to Phase 3

Biogen says it plans to advance diranersen into confirmatory Phase 3 development. That stage would enrol far more patients over a longer period. It is where many promising candidates have failed before. Alzheimer's research is littered with hopeful mid-stage results that later faded.

Timelines in this field are long. A Phase 3 programme can take years to read out. Patients living with the disease today may not benefit directly. That hard truth shadows every hopeful headline in dementia research.

Independent voices urge calm optimism. Advocacy groups welcome any credible progress against a cruel disease. They also caution families against reading too much into one trial. Hope and realism have to travel together. The science, not the press release, will settle the matter.

Still, the tau field has waited years for a clear proof of concept. If the effect survives a larger trial, it could open a second front against the disease. For now, patients and families are told to watch the science closely and keep expectations measured.

Sources

• Alzheimer's Association — Detailed Phase 2 CELIA results for diranersen
• Biogen — Phase 2 CELIA data presented at AAIC 2026
• NeurologyLive — Topline CELIA results show diranersen misses primary endpoint